Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 6689-6698

  Chen, Yushu ^a   Gong, Li ^b   Gao, Ning ^c   Liao, Jichun ^a   Sun, Jiayu ^a   Wang, Yuqing ^a   Wang, Lei ^a   Zhu, Pengjin ^a   Fan, Qing ^a   Wang, Yongqiang Andrew ^d   Zeng, Wen ^b   Mao, Hui ^c   Yang, Lily ^c   Gao, Fabao ^a  

^a SICHUAN UNIVERSITY   (China)

^b Sichuan Primed Bio tech Group Co Ltd   (China)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OCEAN NANOTECH LLC   (United States)

Author keywords

Nonhuman primates; Self healing; Transient harm; uPAR IONP

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; CREATININE; HEMOGLOBIN; IRON; MACROGOL; MAGNETIC IRON OXIDE NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; FERRIC ION; FERRIC OXIDE; MACROGOL DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CHRONIC TOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COATING; DRUG DISTRIBUTION; DRUG HALF LIFE; ERYTHROCYTE COUNT; HEMOGLOBIN BLOOD LEVEL; IRON BLOOD LEVEL; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PILOT STUDY; RHESUS MONKEY; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CHEMISTRY; LIVER; METABOLISM; MOLECULARLY TARGETED THERAPY; SPLEEN; TIME FACTOR;

ANIMALS; FERRIC COMPOUNDS; LIVER; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MALE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; POLYETHYLENE GLYCOLS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SPLEEN; TIME FACTORS;

EID: 84945902586     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S90587     Document Type: Article

References (46)

1. Sullivan DC. Molecular imaging in oncology. Ann Oncol. 2006;17(suppl 10):x287-x292.
2. Xi L, Zhou G, Gao N, et al. Photoacoustic and fluorescence image-guided surgery using a multifunctional targeted nanoprobe. Ann Surg Oncol. 2014;21(5):1602-1609.
3. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92(2):897-965.
4. Estelrich J, Sanchez-Martin MJ, Busquets MA. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomedicine. 2015;10:1727-1741.
5. Chen F, Ehlerding EB, Cai W. Theranostic nanoparticles. J Nucl Med. 2014;55(12):1919-1922.
6. Chen Z, Meng H, Xing G, et al. Acute toxicological effects of copper nanoparticles in vivo. Toxicol Lett. 2006;163(2):109-120.
7. Whitehead A, Stallard N. Opportunities for reduction in acute toxicity testing via improved design. Altern Lab Anim. 2004;32(suppl 2):73-80.
8. Kumari M, Rajak S, Singh SP, et al. Repeated oral dose toxicity of iron oxide nanoparticles: biochemical and histopathological alterations in different tissues of rats. J Nanosci Nanotechnol. 2012;12(3):2149-2159.
9. Liu H, Ma L, Zhao J, et al. Biochemical toxicity of nano-anatase TiO2 particles in mice. Biol Trace Elem Res. 2009;129(1-3):170-180.
10. Sayes CM, Wahi R, Kurian PA, et al. Correlating nanoscale titania structure with toxicity: a cytotoxicity and inflammatory response study with human dermal fibroblasts and human lung epithelial cells. Toxicol Sci. 2006;92(1):174-185.
11. Petrelli F, Borgonovo K, Barni S. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother. 2010;11(8):1413-1432.
12. Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast. 2009;18(4):218-224.
13. Ploug M, Østergaard S, Gårdsvoll H, et al. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry. 2001;40(40):12157-12168.
14. Baldini E, Sorrenti S, D'Armiento E, Di Matteo FM, Catania A, Ulisse S. The urokinase plasminogen activating system in thyroid cancer: clinical implications. G Chir. 2012;33(10):305-310.
15. Mekkawy AH, Morris DL, Pourgholami MH. Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 2009;5(9):1487-1499.
16. Romer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 2004;10(19):2359-2376.
17. Yang L, Sajja HK, Cao Z, et al. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection. Theranostics. 2013;4(1):106-118.
18. Yang L, Peng XH, Wang YA, et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res. 2009;15(14):4722-4732.
19. Liu D, Overbey D, Watkinson L, Giblin MF. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR). Bioconjug Chem. 2009;20(5):888-894.
20. Wang F, Eric Knabe W, Li L, et al. Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. Bioorg Med Chem. 2012;20(15):4760-4773.
21. Li R, Zheng K, Hu P, et al. A novel tumor targeting drug carrier for optical imaging and therapy. Theranostics. 2014;4(6):642-659.
22. Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013;7(3):2078-2089.
23. Patterson TA, Twaddle NC, Roegge CS, Callicott RJ, Fisher JW, Doerge DR. Concurrent determination of bisphenol A pharmacokinetics in maternal and fetal rhesus monkeys. Toxicol Appl Pharmacol. 2013;267(1):41-48.
24. Vom Saal FS, VandeVoort CA, Taylor JA, Welshons WV, Toutain PL, Hunt PA. Bisphenol A (BPA) pharmacokinetics with daily oral bolus or continuous exposure via silastic capsules in pregnant rhesus monkeys: relevance for human exposures. Reprod Toxicol. 2014;45:105-116.
25. Fisher JW, Twaddle NC, Vanlandingham M, Doerge DR. Pharmacokinetic modeling: prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans. Toxicol Appl Pharmacol. 2011;257(1):122-136.
26. Yang P, Han P, Hou J, et al. Electrocardiographic characterization of rhesus monkey model of ischemic myocardial infarction induced by left anterior descending artery ligation. Cardiovasc Toxicol. 2011;11(4):365-372.
27. Taylor JA, Vom Saal FS, Welshons WV, et al. Similarity of bisphenol A pharmacokinetics in rhesus monkeys and mice: relevance for human exposure. Environ Health Perspect. 2011;119(4):422-430.
28. Chen H, Wang L, Yu Q, et al. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer. Int J Nanomedicine. 2013;8:3781-3794.
29. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004;17(7):484-499.
30. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34(1):23-38.
31. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62(3):284-304.
32. Jun YW, Lee JH, Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed Engl. 2008;47(28):5122-5135.
33. Huang J, Zhong X, Wang L, Yang L, Mao H. Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics. 2012;2(1):86-102.
34. Xie J, Chen K, Huang J, et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials. 2010;31(11):3016-3022.
35. Alarifi S, Ali D, Al-Doaiss AA, Ali BA, Ahmed M, Al-Khedhairy AA. Histologic and apoptotic changes induced by titanium dioxide nanoparticles in the livers of rats. Int J Nanomedicine. 2013;8:3937-3943.
36. Cawello W, Fichtner A, Boekens H, Braun M. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine. Eur J Drug Metab Pharmacokinet. 2014;39(3):155-163.
37. Concepcion Navarro M, Pilar Montilla M, Martin A, Jimenez J, Pilar Utrilla M. Free radical scavenger and antihepatotoxic activity of Rosmarinus tomentosus. Planta Med. 1993;59(4):312-314.
38. Kim TY, Kim DJ. Acute-on-chronic liver failure. Clin Mol Hepatol. 2013;19(4):349-359.
39. Zamora Nava LE, Aguirre Valadez J, Chavez-Tapia NC, Torre A. Acute-on-chronic liver failure: a review. Ther Clin Risk Manag. 2014;10:295-303.
40. Khare P, Sonane M, Pandey R, Ali S, Gupta KC, Satish A. Adverse effects of TiO2 and ZnO nanoparticles in soil nematode, Caenorhabditis elegans. J Biomed Nanotechnol. 2011;7(1):116-117.
41. Maiti S. Nanotoxicity of gold and iron nanoparticles. J Biomed Nanotechnol. 2011;7(1):65.
42. You J, Zhou J, Zhou M, et al. Pharmacokinetics, clearance, and biosafety of polyethylene glycol-coated hollow gold nanospheres. Part Fibre Toxicol. 2014;11:26.
43. Sarhan OM, Hussein RM. Effects of intraperitoneally injected silver nanoparticles on histological structures and blood parameters in the albino rat. Int J Nanomedicine. 2014;9:1505-1517.
44. Zheng JC, Lei N, He QC, et al. PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of alpha-momorcharin in vivo. Immunopharmacol Immunotoxicol. 2012;34(5):866-873.
45. Esmaeillou M, Moharamnejad M, Hsankhani R, Tehrani AA, Maadi H. Toxicity of ZnO nanoparticles in healthy adult mice. Environ Toxicol Pharmacol. 2013;35(1):67-71.
46. Yang L, Mao H, Cao Z, et al. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology. 2009;136(5):1514-1525.e2.